Salvage treatment with irinotecan/cisplatin versus pemetrexed/cisplatin in patients with non-small cell lung cancer pre-treated with a non-platinum-based regimen in the first-line setting: a randomized phase II study of the Hellenic Oncology Research Group (HORG)

[1]  Ahmedin Jemal,et al.  Cancer Statistics for Hispanics/Latinos, 2018 , 2018, CA: a cancer journal for clinicians.

[2]  M. Socinski,et al.  Treatment of Stage IV Non-small Cell Lung Cancer Diagnosis and Management of Lung Cancer , 3 rd ed : American College of Chest Physicians Evidence-Based Clinical Practice Guidelines , 2013 .

[3]  R. Labianca,et al.  Pemetrexed versus pemetrexed and carboplatin as second-line chemotherapy in advanced non-small-cell lung cancer: results of the GOIRC 02-2006 randomized phase II study and pooled analysis with the NVALT7 trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Deepa Naishadham,et al.  Cancer statistics for Hispanics/Latinos, 2012 , 2012, CA: a cancer journal for clinicians.

[5]  M. Shi,et al.  Non-platinum regimens of gemcitabine plus docetaxel versus platinum-based regimens in first-line treatment of advanced non-small cell lung cancer: a meta-analysis on 9 randomized controlled trials , 2012, Cancer Chemotherapy and Pharmacology.

[6]  Thomas J. Smith,et al.  2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  S. Agelaki,et al.  A retrospective analysis of non-platinum-based first- and second-line chemotherapy in patients with advanced non-small cell lung cancer. , 2010, Anticancer research.

[8]  V. Georgoulias,et al.  Non-Platinum-Based First-Line Followed by Platinum-Based Second-Line Chemotherapy or the Reverse Sequence in Patients with Advanced Non-Small Cell Lung Cancer: A Retrospective Analysis by the Lung Cancer Group of the Hellenic Oncology Research Group , 2010, Oncology.

[9]  S. Jiao,et al.  Pemetrexed plus cisplatin/carboplatin in previously treated locally advanced or metastatic non-small cell lung cancer patients , 2010, Journal of experimental & clinical cancer research : CR.

[10]  G. Scagliotti,et al.  Randomised multicenter phase II study of two schedules of docetaxel and gemcitabine or cisplatin/gemcitabine followed by docetaxel as first line treatment for advanced non-small cell lung cancer. , 2009, Lung cancer.

[11]  F. de Marinis,et al.  Pemetrexed as first-line therapy for non-squamous non-small cell lung cancer , 2009, Therapeutics and clinical risk management.

[12]  C. Gridelli,et al.  Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  M. Lázaro,et al.  A phase II randomized trial of gemcitabine-docetaxel versus gemcitabine-cisplatin in patients with advanced non-small cell lung carcinoma , 2009, Cancer Chemotherapy and Pharmacology.

[14]  Jayne Tierney,et al.  Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Johan Vansteenkiste,et al.  Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  J. Rigas,et al.  Phase III multicenter web-based study demonstrating survival equivalents of nonplatinum-based chemotherapy for advanced non-small cell lung cancer (NSCLC): Subgroup analysis from D0112 , 2008 .

[17]  N. Suttorp,et al.  Docetaxel/gemcitabine or cisplatin/gemcitabine followed by docetaxel in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC): results of a multicentre randomized phase II trial , 2007, Cancer Chemotherapy and Pharmacology.

[18]  K. Bouzid,et al.  Gemcitabine/docetaxel (GD) versus gemcitabine/cisplatin (GC) in stage III/IV non-small cell lung cancer (NSCLC): Preliminary results. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  A. Yoshimura,et al.  Docetaxel in Combination with Either Cisplatin or Gemcitabine in Unresectable Non-small Cell Lung Carcinoma: A Randomized Phase II Study by the Japan Lung Cancer Cooperative Clinical Study Group , 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[20]  K. Syrigos,et al.  Second-line treatment with irinotecan plus cisplatin vs cisplatin of patients with advanced non-small-cell lung cancer pretreated with taxanes and gemcitabine: a multicenter randomised phase II study , 2005, British Journal of Cancer.

[21]  F. Shepherd,et al.  Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  M. Carey,et al.  Determining the relationship between toxicity and quality of life in an ovarian cancer chemotherapy clinical trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Miklos Pless,et al.  Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  I. Vlachonikolis,et al.  Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial , 2001, The Lancet.

[25]  V. Georgoulias,et al.  Salvage treatment of advanced non-small-cell lung cancer previously treated with docetaxel-based front-line chemotherapy with irinotecan (CPT-11) in combination with cisplatin. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  N. Saijo,et al.  Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells. , 1996, Cancer research.

[27]  S. Kaasa,et al.  Polychemotherapy in advanced non small cell lung cancer: a meta-analysis , 1993, The Lancet.

[28]  J. Crowley,et al.  Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  Wenyaw Chan,et al.  Statistical Methods in Medical Research , 2013, Model. Assist. Stat. Appl..

[30]  G. Guyatt,et al.  Physicians Evidence-Based Clinical Practice Development : American College of Chest Thrombolytic Therapy Guideline Methodology for Antithrombotic and , 2008 .

[31]  D. Purdie.  Statistical Methods in Medical Research, 4th edn , 2003 .

[32]  P. Bonomi,et al.  Treatment of Stage IV Non-Small Cell Lung Cancer , 2002 .

[33]  N. Sobol,et al.  Preliminary results , 2020, Asymptotic Analysis of Random Walks: Light-Tailed Distributions.